Artielle ImmunoTherapeutics   Report issue

For profit Phase 1
Founded: San Mateo CA United States (2004)
Status: Left NME R&D (2016)

Organization Overview

First Clinical Trial
2006
NCT00411723
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (1)

rtl1000 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 1)

Multiple Sclerosis, Chronic Progressive (Phase 1)

Multiple Sclerosis, Relapsing-Remitting (Phase 1)

Sclerosis (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1